Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Clinical pharmacokinetics and metabolism of nimesulide

Clinical pharmacokinetics and metabolism of nimesulide Nimesulide is a selective COX-2 inhibitor used in a variety of inflammatory, pain and fever states. After oral administration the drug is rapidly and extensively absorbed. Nimesulide is rapidly distributed, extensively bound to albumin and eliminated with a terminal half-life of about 4 h. Excretion of the unchanged drug in urine and faeces is negligible. Nimesulide is mainly cleared from the body by metabolic transformation and the principal active metabolite is the 4′-hydroxyl derivative (M1). After oral administration, nimesulide shows linear pharmacokinetics in the dose range from 25 to 100 mg. The usual therapeutic regimen is 100 mg p.o. twice daily. The pharmacokinetic profiles of nimesulide and M1 in children and elderly do not differ from those of healthy young subjects. The pharmacokinetics of nimesulide and M1 are not altered in moderate renal impairment. Pharmacokinetic interactions between nimesulide and other drugs given in combination were absent or of no clinical significance. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Inflammopharmacology Springer Journals

Clinical pharmacokinetics and metabolism of nimesulide

Inflammopharmacology , Volume 9 (2) – Dec 20, 2004

Loading next page...
 
/lp/springer-journals/clinical-pharmacokinetics-and-metabolism-of-nimesulide-DBA8UVf7i5

References (88)

Publisher
Springer Journals
Copyright
Copyright © 2001 by VSP 2001
Subject
Biomedicine; Pharmacology/Toxicology; Allergology; Rheumatology
ISSN
0925-4692
eISSN
1568-5608
DOI
10.1163/156856001300248353
Publisher site
See Article on Publisher Site

Abstract

Nimesulide is a selective COX-2 inhibitor used in a variety of inflammatory, pain and fever states. After oral administration the drug is rapidly and extensively absorbed. Nimesulide is rapidly distributed, extensively bound to albumin and eliminated with a terminal half-life of about 4 h. Excretion of the unchanged drug in urine and faeces is negligible. Nimesulide is mainly cleared from the body by metabolic transformation and the principal active metabolite is the 4′-hydroxyl derivative (M1). After oral administration, nimesulide shows linear pharmacokinetics in the dose range from 25 to 100 mg. The usual therapeutic regimen is 100 mg p.o. twice daily. The pharmacokinetic profiles of nimesulide and M1 in children and elderly do not differ from those of healthy young subjects. The pharmacokinetics of nimesulide and M1 are not altered in moderate renal impairment. Pharmacokinetic interactions between nimesulide and other drugs given in combination were absent or of no clinical significance.

Journal

InflammopharmacologySpringer Journals

Published: Dec 20, 2004

There are no references for this article.